Andrew E. Sloan Lab
Innovative Neuro-Oncology Research
Andrew E. Sloan
Professor & Vice Chairman, Department of Neurosurgery
Peter D. Cristal Chair of Neurosurgical Oncology
Director, Brain Tumor & Neuro-Oncology Center
Director, Center of Excellence for Translational Neuro-Oncology
Distinguished Surgeon & Senior Staff Neurosurgeon
University Hospitals-Cleveland Medical Center & Seidman Cancer Center, Case Comprehensive Cancer Center
Dr. Sloan focuses on clinical and translational approaches to the treatment of malignant brain tumors and has been funded by NIH, NCI, the Ohio Third Frontier organization, the American Society of Clinical Oncology (ASCO), The American Brain Tumor Association (ABTA), the Adult Brain Tumor Consortium (ABTC), Howard Hughes Medical Institute (HHMI), and other national organizations, as well as several pharmaceutical companies. He has more than 210 peer-reviewed publications, 6 US patents and INDs, and more than 600 invited presentations, and sits on the editorial boards of several neurosurgical and general medical journals.
David Soler, Ph.D.
Dr. David Soler received his Ph.D. in Molecular Biology at Kent State University and a M.S. in Immunology at the University of Barcelona. He obtained an undergraduate double major in Biochemistry and Biology at the University of Navarra. He completed his postdoctoral degree in the Department of Dermatology at Case Western Reserve University. He currently has 18 first author papers. His current interests include developing blood-based liquid-biopsy tests to identify Glioblastoma multiforme (GBM) recurrence. He is also focused on finding innovative and practical ways to combat GBM using CAR-T cells. He is very open to collaborations and to find innovative ways to tackle human disease and basic biology problems such as mass-producing membrane proteins for structural studies or rescuing plasma membrane expression for problem proteins.
We are proud to showcase the results of research undertaken by members of our interdisciplinary Scientific Research Laboratory. Our work and findings have been published in a number of prestigious publications in our field.
A Liquid Biopsy to Assess Brain Tumor Recurrence: Presence of Circulating Mo-MDSC and CD14+ VNN2+ Myeloid Cells as Biomarkers that Distinguish Brain Metastasis from Radiation Necrosis Following Stereotactic Radiosurgery
21 August 2020
Neurosurgery 88(1): E67-E72
Proteins Inform Survival-Based Differences in Patients with Glioblastoma
17 March 2020
Neuro-Oncology Advances 2(1) 1-11
Plant Virus-Like Particle In Situ Vaccine for Intracranial Glioma Immunotherapy
10 April 2019
Cancers (Basel) 11(4): 515
The Ratio of HLA-DR and VNN2+ Expression on CD14+ Myeloid Derived Suppressor Cells Can Distinguish Glioblastoma from Radiation Necrosis Patients
27 May 2017
Neurooncol 134(1): 189-196
Targeting Glioma Stem Cells Through Combined BMI1 and EZH2 Inhibition
9 October 2017
Nature Medicine 23: 1352-1361